Glyceryl monostearate based nanoparticles of mefenamic acid: Fabrication and invitro characterization

Drug Invention Today

Volumn 5, Issue 3, 2013, Pages 246-250

  Kumar, Rabee ^a   Yasir, Mohd ^a   Saraf, Shubhini A ^b   Gaur, Praveen K ^a   Kumar, Yatendra ^a   Singh, Alok Pratap ^a  

^a ITS Paramedical College (Pharmacy)   (India)

^b BABASAHEB BHIMRAO AMBEDKAR UNIVERSITY   (India)

Author keywords

Glyceryl monostearate (GMS); Mefenamic acid (MF); Solid lipid nanoparticles (SLNs); Solvent emulsification diffusion technique

Indexed keywords

GLYCEROL STEARATE; MEFENAMIC ACID; PALMITIC ACID; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; STEARIC ACID; SURFACTANT;

ARTICLE; CHEMICAL PARAMETERS; CHEMICAL PROCEDURES; CHEMICAL STRUCTURE; CONTROLLED STUDY; DIFFUSION; DRUG SOLUBILITY; EMULSION; FICKIAN DIFFUSION; IN VITRO STUDY; NANOFABRICATION; PARTICLE SIZE; PERCENT DRUG ENTRAPMENT EFFICIENCY; PERCENT DRUG LOADING; POLYDISPERSITY INDEX; SOLVENT EMULSIFICATION DIFFUSION TECHNIQUE; SURFACE PROPERTY; ZETA POTENTIAL;

EID: 84884413538     PISSN: 09757619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dit.2013.06.011     Document Type: Article

References (10)

1. Yamazaki R., Kawai S., Matsuzaki T., et al. Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmaco 1997, 329:181-187.
2. Djordjevic J., Michniak B., Uhrich K.E. Amphiphilic star-like macromolecules as novel carriers for topical delivery of nonsteroidal anti-inflammatory drugs. AAPS Pharm Sci 2003, 5:1-12.
3. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 50:161-177.
4. Jensen L.B., Magnussson E., Gunnarsson L., Vermehren C., Nielsen H.M., Petersson K. Corticosteroid solubility and lipid polarity control release from solid lipid Nanoparticles. Int J Pharm 2010, 390:53-60.
5. Shah A.K., Date A.A., Joshi M.D., Patravale V.B. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm 2007, 345:163-171.
6. Singh A.P., Saraf S.K., Saraf S.A. SLN approach for nose-to-brain delivery of Alprazolam. Drug Del Trans Res 2012, 2:498-507.
7. Varshosaz J., Tabbakhian M., Mohammadi M.Y. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Lipo Res 2010, 20:286-296.
8. Bourne D.W.A. Pharmacokinetics. Modern Pharmaceutics 2002, 67-92. Marcel Dekker Publishing Inc, New York, NY. 4th ed. G.S. Banker, C.T. Rhodes (Eds.).
9. Korsmeyer R.W., Gurny R., Doelker E., Buri P., Pappas N.A. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 1983, 15:25-35.
10. ICH Harmonized Tripartite Guidelines, Stability Testing of New Drug Substances and Product 2003, 8. ICH Committee.